Gilead Sciences to Acquire Immunomedics

Trodelvy will Accelerate Gilead’s Emerging and Complementary Oncology Pipeline

15-Sep-2020 - Gilead Sciences, Inc. and Immunomedics announced that the companies have entered into a definitive agreement pursuant to which Gilead will acquire Immunomedics for $88.00 per share in cash. The transaction, which values Immunomedics at approximately $21 billion, was unanimously approved by both ...

UCB announces start of phase III programme with epratuzumab for patients with moderate to severe systemic lupus erythematosus

Phase III programme follows positive phase IIb study EMBLEM, which showed that epratuzumab reduced disease activity over a 12 week treatment period

15-Dec-2010 - UCB and U.S. based partner Immunomedics Inc. announced the enrollment of the first patient into EMBODY™ 1, one of two pivotal phase III studies of epratuzumab in patients with moderate to severe systemic lupus erythematosus (SLE). Patient enrollment for EMBODY™ 2 has also begun. Both studies ...

Epratuzumab phase IIb data show pipeline drug had positive effect in patients suffering from systemic lupus erythematosus

11-Nov-2010 - UCB and U.S. based partner Immunomedics Inc.announced that results from the phase IIB study, EMBLEM™, showed that certain doses of epratuzumab were associated with a meaningful and statistically significant reduction in disease activity in adult patients with moderate to severe active SLE. The ...

Epratuzumab data from phase IIb EMBLEM study presented at 9th International Congress on Systemic Lupus Erythematosus

29-Jun-2010 - UCB and Immunomedics Inc. announced that data for lupus drug candidate, epratuzumab, were presented at the 9th International Congress on Systemic Lupus Erythematosus in Vancouver, Canada. These data showed that, in patients with moderate to severe systemic lupus erythematosus (SLE), epratuzumab ...

New data from EMBLEM study shows epratuzumab provided efficacy for patients suffering from systemic lupus erythematosus

17-Jun-2010 - UCB and Immunomedics Inc. announced new lupus drug candidate, epratuzumab, provided a significant reduction in disease activity in patients with moderate to severe active systemic lupus erythematosus (SLE). Data presented at the European League Against Rheumatism (EULAR) meeting in Rome from the ...

UCB and Immunomedics announce positive results for epratuzumab phase IIb study in systemic lupus erythematosus (SLE)

Data from phase IIb dose and regimen-ranging study demonstrate clinically meaningful treatment effect

28-Aug-2009 - UCB and Immunomedics announced top-line results from UCB's Phase IIb clinical study comparing epratuzumab to placebo in patients with systemic lupus erythematosus (SLE, also commonly known as lupus). The data from the 12-week dose and regimen-ranging study demonstrated clinical meaningful ...

UCB and Immunomedics announce worldwide development collaboration and license agreement for Epratuzumab

11-May-2006 - UCB and Immunomedics, Inc. announced a collaboration and license agreement for Immunomedics' lead product, epratuzumab. The agreement grants UCB the exclusive worldwide rights to develop, market and sell epratuzumab for all autoimmune disease indications. Epratuzumab's most advanced program is ...